

# Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction?

<b>Submission date</b> 21/02/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 29/03/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 10/07/2017	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Narasimharajapura Rajendra

### Contact details

Department of Clinical Pharmacology  
Level 7  
Ninewells Hospital  
Dundee  
United Kingdom  
DD1 9SY

## Additional identifiers

### Protocol serial number

RAJ001

## Study information

### Scientific Title

Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction?

**Study objectives**

Allopurinol, by inhibiting xanthine oxidase brings about a reduction in reactive oxygen species, thereby preventing adverse remodelling

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Regional Ethics Committee, 07/12/2005, ref: 05/S1401/171

**Study design**

Randomised double-blind placebo-controlled parallel group

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Myocardial infarction

**Interventions**

Allopurinol versus placebo

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Allopurinol

**Primary outcome(s)**

Assessment of remodelling

**Key secondary outcome(s)**

Brain natriuretic peptide (BNP)

**Completion date**

02/04/2008

**Eligibility****Key inclusion criteria**

Post myocardial infarction - days 3 to 14

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. Renal failure
2. Concomitant warfarin therapy
3. Allopurinol allergy

**Date of first enrolment**

10/02/2006

**Date of final enrolment**

02/04/2008

**Locations****Countries of recruitment**

United Kingdom

Scotland

**Study participating centre**

Ninewells Hospital

Dundee

United Kingdom

DD1 9SY

**Sponsor information****Organisation**

University of Dundee (UK)

**ROR**

<https://ror.org/03h2bxq36>

**Funder(s)**

**Funder type**

Charity

**Funder Name**

British Heart Foundation

**Alternative Name(s)**

the\_bhf, The British Heart Foundation, BHF

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Trusts, charities, foundations (both public and private)

**Location**

United Kingdom

## Results and Publications

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes